Eloxx Pharmaceuticals, Inc. quarterly report, Q3 FY2013

Business context and reporting period

Filing identity discrepancy: The supplied filing is for Senesco Technologies, Inc., not Eloxx Pharmaceuticals, Inc. It is a Form 10-Q for the fiscal quarter ended March 31, 2013 (the third quarter of fiscal 2013), not 2012 Q3. The summary below reflects the filing text provided.

Senesco was a development-stage biotechnology company pursuing human therapeutics, including SNS01-T for multiple myeloma and other B-cell cancers, and licensing agricultural gene technologies. Financial statements are unaudited.

Financial performance and position

No meaningful revenue-based margin is reported because revenue was zero in the current periods. The company reported a $785,171 loss on extinguishment of debt and a $271,831 gain from changes in warrant-liability fair value for the nine-month period; these items affect comparability of net loss.

Material changes versus prior comparable periods

• Quarterly net loss narrowed by $224,076 (21.1%), primarily due to warrant-liability fair-value changes and lower general and administrative and research and development expenses.
• Nine-month net loss increased by $564,709 (15.6%), reflecting no current-period licensing revenue versus $200,000 in the prior period and higher non-operating expense, partly offset by lower operating expenses.
• Nine-month research and development expense declined 17.1% to $1.597 million; general and administrative expense declined 6.0% to $1.993 million.
• Cash declined $420,288 from June 30, 2012. Financing activities provided $2.931 million, principally from the January 2013 equity offering.

Outlook, risks and unusual items

• Management estimated that March 31 cash plus approximately $1.125 million net proceeds from a May 2013 stock placement would fund operations only through November 2013. Additional capital was needed to fund operations through at least March 31, 2014; the filing warns financing may not be available on acceptable terms.
• The filing describes recurring losses and negative operating cash flows as raising substantial doubt about the company’s ability to continue as a going concern. It expected losses to continue for several years and could not predict when, if ever, it would become profitable.
• In January 2013, Senesco raised $3.0 million gross through a registered offering of 30 million shares and warrants; net proceeds were $2.849 million. The May offering issued 41,833,335 shares at $0.03 for approximately $1.125 million net.
• The May financing reset the conversion price of outstanding preferred stock, increasing potential common shares issuable on conversion. Further dilution may arise from outstanding warrants, options and preferred stock. In April, the company exchanged warrants to buy 10.5 million shares for 5.25 million common shares.
• The company was delisted from NYSE MKT in November 2012 and quoted on OTCQB. It also reported that a biofuels license agreement was terminated after a licensee breach and was replaced by a new agreement in May 2013.
• SNS01-T was in a Phase 1b/2a dose-escalation study. The first two cohorts were completed; the company reported acceptable safety and tolerability and stable disease in two of six evaluable patients, and was recruiting for the third cohort. Clinical efficacy remains uncertain.
• Key risks include clinical-trial and regulatory failure, dependence on a principal technology and external research partners, uncertain licensing and commercialization revenue, patent and product-liability exposure, and limited trading liquidity. Management said disclosure controls were effective and reported no material internal-control changes during the quarter.

Important facts for investors to verify

1. Confirm the issuer and period: this source identifies Senesco Technologies and the quarter ended March 31, 2013, despite the request metadata naming Eloxx and 2012 Q3.
2. Review the going-concern disclosure, projected November 2013 cash runway, and need and ability to raise further capital.
3. Check the terms and proceeds of the January and May equity financings, preferred-stock conversion resets, warrant obligations, and resulting dilution.
4. Verify the clinical-trial status and underlying data for SNS01-T; the filing reports early-stage safety and limited stable-disease observations, not established efficacy.
5. Assess the demand line of credit, the OTCQB trading status, and the timing and reliability of any future license milestones or royalties.